COGT Stock Summary and Trading Ideas (Cogent Biosciences | NASDAQ:COGT)

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Cogent Biosciences trades on the NASDAQ stock market under the symbol COGT.

As of March 16, 2026, COGT stock price climbed to $35.89 with 1,565,700 million shares trading.

COGT has a beta of 1.60, meaning it tends to be more sensitive to market movements. COGT has a correlation of 0.06 to the broad based SPY ETF.

COGT has a market cap of $5.83 billion. This is considered a Mid Cap stock.

In the last 3 years, COGT traded as high as $43.73 and as low as $3.67.

The top ETF exchange traded funds that COGT belongs to (by Net Assets): VTI, IWM, XBI, VXF, VB.

COGT has outperformed the market in the last year with a return of +392.3%, while the SPY ETF gained +22.8%. However, in the most recent history, COGT shares have underperformed the stock market with its stock returning -14.8% in the last 3 month period and -7.6% for the last 2 week period, while SPY has returned -1.5% and -2.4%, respectively.

COGT support price is $32.82 and resistance is $35.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COGT shares will trade within this expected range on the day.